Investor Relations

Stock Quote - Ticker Tape

 

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o Press Releases  
  AUGUST 19, 2014
NEW STORY CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada
  AUGUST 8, 2014
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results
  AUGUST 1, 2014
NEW STORY CEL-SCI Achieves Milestone in July with Total of 232 Patients Enrolled To Date in Its Phase III Head and Neck Cancer Trial
  JULY 30, 2014
NEW STORY France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in Its Global Phase III Head and Neck Cancer Trial
  JULY 22, 2014
NEW STORY CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey
  JULY 17, 2014
NEW STORY CEL-SCI Expands Its Phase III Head and Neck Cancer Trial into Sri Lanka
  JULY 15, 2014
NEW STORY CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
  JULY 11, 2014
NEW STORY CEL-SCI Presents Rheumatoid Arthritis Data at the 12th Vaccines Research & Development: All Things Considered Conference
 

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com